Regeneron Pharmaceuticals, Inc. (REGN)
Here's Why Regeneron (REGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Regeneron's Applications for gMG Drug Accepted by FDA and EMA
Regeneron's cemdisiran won FDA Priority Review and EMA filing acceptance for gMG, backed by phase III data and a potentially unique dosing schedule.
Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and promising pipeline assets. EYLEA HD U.S. sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. Recent FDA approvals and pending regulatory decisions for EYLEA HD and CEMDISIRAN provide near-term catalysts and franchise durability.
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
If you're looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech innovators.
Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
